<p>/PRNewswire/ -- 中国九洲大药房公司（Nasdaq:CJJD）（&#34;九洲大药房&#34;或&#34;公司&#34;）是一家领先的线上和线下零售商、药品及其他健康产品的批发分销商以及中国的医疗服务提供者，今天宣布已达成战略重组计划的最终协议，以转型为轻资产、以批发为重点的公司，精简运营并提升盈利能力。</p>
<p>此次重组涉及两项主要交易（&#34;交易&#34;）：</p>
<ul>
<li>收购交易：通过发行 2,225,000 股普通股进行股权交换，收购快速成长的药品批发公司 Allright（杭州）互联网科技有限公司（&#34;Allright&#34;），这代表了交易完成后公司已发行和流通普通股的 38%；以及</li>
<li>剥离交易：将九洲大药房的药品零售业务出售给现任首席执行官兼董事刘雷和董事李琦，他们及其关联方目前共同持有公司约 41% 的流通普通股，作为交换，刘、琦及其关联方将向公司交回其持有的共计 2,548,353 股普通股。</li>
</ul>
<p>预计交易将在 2025 年第一季度完成，需满足包括九洲大药房股东批准在内的惯常成交条件。交易完成后，刘和琦预计将辞去公司董事会及其他任何职务（包括首席执行官），而 Allright 的最终股东孔灵涛将加入董事会。各方同意，公司的现任首席财务官赵峰将担任临时首席执行官，以确保业务的持续运营和 Allright 业务的整合。</p>
<p>九洲大药房董事长兼首席执行官刘雷先生评论道：&#34;此次重组标志着 CJJD 的一个关键时刻，我们将从高成本的零售领域转型为以批发为重点的模式。虽然我将把重心转向我深耕的零售业务，但我相信这一转型将提升运营效率，并为 CJJD 的股东创造长期价值。我期待在新领导下看到批发业务蓬勃发展。&#34;</p>
<p>Allright 的最终股东及即将加入董事会的孔灵涛先生表示：&#34;我很高兴能与 CJJD 携手共建更强大的批发平台。Allright 的增长轨迹与 CJJD 的战略愿景高度契合，我相信我们的专业结合将为药品批发市场创造新的扩展和成功机会。&#34;</p>
<p>现任首席财务官及即将担任临时首席执行官的赵峰先生补充道：&#34;在这个转型时期，我很荣幸能担任临时首席执行官。我想感谢刘先生在将 CJJD 建设成今天这样强大公司的领导和奉献。随着我们向以批发为驱动的模式转型，我期待与孔先生及我们的团队紧密合作，执行我们的战略愿景，确保 Allright 业务的无缝整合。我们的重点将继续放在加强批发业务、提高效率，并为 CJJD 的长期成功奠定基础。&#34;</p>
<p><strong>关于中国九洲大药房公司</strong></p>
<p>中国九洲大药房公司（&#34;九洲大药房&#34;或&#34;公司&#34;）是一家领先的线上和线下零售商及药品和其他健康产品的批发分销商，同时也是中国的医疗服务提供者。九洲大药房目前运营着一家在线药房和零售药店，现场有持证医生提供咨询、检查和常见疾病的治疗。它也是类似于其药房所销售产品的批发分销商。有关公司的更多信息，请访问 http://jiuzhou360.com。公司定期在其网站上发布重要信息。</p>
<p><strong>前瞻性声明</strong></p>
<p>本新闻稿包含关于公司未来预期、计划和前景的信息，这些信息构成了 1995 年美国私人证券诉讼改革法案、1933 年证券法第 27A 条及 1934 年证券交易法第 21E 条所定义的前瞻性声明。新闻稿中除历史事实声明外的所有声明，包括关于拟议交易的好处和预计完成时间的声明，均为前瞻性声明。这些前瞻性声明中的一些可以通过使用前瞻性词汇来识别，包括 “可能”、“应该”、“期望”、“打算”、“将”、“估计”、“预期”、“相信”、“预测”、“计划”、“目标”、“项目”、“可以”、“会”、“将”、“继续”、“预测” 或这些术语的否定形式或变体或类似表达。所有前瞻性声明均基于估计、预测和假设，尽管公司及其管理层认为这些是合理的，但本质上是不确定的。实际结果可能因多种因素而与历史结果或这些前瞻性声明所指示的结果有重大差异，包括但不限于与公司及时完成交易或根本无法完成交易的能力、实施其商业计划和战略的能力、筹集额外资金的能力、维持和发展其业务的能力、批发定价和药品需求的波动、经营结果的变化、维持和提升品牌的能力、新产品和服务的开发和推出、成功整合收购的公司、技术和资产到其产品和服务组合中的能力、市场营销和其他业务发展举措、与供应商和医疗服务提供者的关系、行业竞争、一般政府监管、经济状况、对关键人员的依赖、吸引、招聘和留住具备满足客户要求的技术技能和经验的人员的能力，以及保护其知识产权的能力。公司鼓励您查看可能影响其未来结果的其他风险因素，这些因素在公司的年度报告和向证券交易委员会（“SEC”）的其他文件中有所披露。</p>
<p>您不应对前瞻性声明过度依赖，这些声明仅在作出时有效。公司不保证合并后的公司将实现其预期结果。除法律另有要求外，公司不承担更新这些前瞻性声明的义务。</p>
<p><strong>关于拟议交易的重要信息及获取途径</strong></p>
<p>本新闻稿涉及与九洲大药房相关的某些拟议交易。公司将向 SEC 提交与交易相关的代理声明。代理声明将发送给截至投票交易的适用记录日期的所有公司股东。公司还将向 SEC 提交与交易相关的其他文件。</p>
<p>在做出任何投票决定之前，建议股东阅读代理声明、任何修订及所有其他与交易相关的相关文件，这些文件将在与交易相关时提交给 SEC，因为它们将包含关于公司和交易的重要信息。</p>
<p>投资者和股东可以通过 SEC 维护的网站 www.sec.gov 免费获取代理声明及公司向 SEC 提交的所有其他相关文件。公司向 SEC 提交的文件也可以在公司网站 http://jiuzhou360.com/investors/sec_filings 上免费获取。</p>
<p>SEC 或任何州证券监管机构均未批准或不批准本通讯中描述的交易，未对交易或相关交易的优点或公平性进行评估，也未对本通讯中的披露的充分性或准确性进行评估。任何相反的陈述均构成刑事犯罪。</p>
<p><strong>无报价或招揽</strong></p>
<p>本新闻稿既不是代理的招揽，也不是购买要约或出售任何证券的招揽，也不是任何可能在拟议交易进行时向 SEC 提交的代理声明或其他文件的替代品。</p>
<p><strong>如需更多信息，请联系：</strong></p>
<p><strong>公司联系人：</strong></p>
<p>Frank Zhao</p>
<p>首席财务官</p>
<p>+86-571-88077108</p>
<p>frank.zhao@jojodrugstores.com</p>
<p><strong>投资者关系联系人：</strong></p>
<p>Tina Xiao</p>
<p>Ascent Investor Relations LLC</p>
<p>+1-646-932-7242</p>
<p>investors@ascent-ir.com</p>
<p>来源：中国九洲大药房股份有限公司</p>

九洲大药房

RDGT

<p>中国九洲大药房（Nasdaq:CJJD）宣布进行战略重组，专注于其批发业务，以提高盈利能力。这包括收购 Allright（杭州）互联网科技有限公司，并将其零售业务出售给现任首席执行官刘雷和董事李琦。交易预计将在 2025 年第一季度完成，待股东批准。重组后，Frank Zhao 将担任临时首席执行官。公司旨在通过这一转型提高运营效率，为股东创造长期价值</p>

<p>, /PRNewswire/ --China Jo-Jo Drugstores, Inc. (Nasdaq:CJJD) (&#34;Jo-Jo Drugstores&#34; or the &#34;Company&#34;), a leading online and offline retailer, wholesale distributor of pharmaceutical and other healthcare products and healthcare provider inChina, today announcedit has entered into definitive agreements for a strategic restructuring initiative to transition into an asset-light, wholesale-focused company, streamlining operations and enhancing profitability.</p>
<div class="lb-trans"><p>/PRNewswire/ -- 中国九洲大药房公司（Nasdaq:CJJD）（&#34;九洲大药房&#34;或&#34;公司&#34;）是一家领先的线上和线下零售商、药品及其他健康产品的批发分销商以及中国的医疗服务提供者，今天宣布已达成战略重组计划的最终协议，以转型为轻资产、以批发为重点的公司，精简运营并提升盈利能力。</p>
</div><p>The restructuring involved two major transactions (the &#34;Transactions&#34;):</p>
<div class="lb-trans"><p>此次重组涉及两项主要交易（&#34;交易&#34;）：</p>
</div><ul>
<li>Acquisition transaction: The acquisition of Allright (Hangzhou) Internet Technology Co. Ltd. (&#34;Allright&#34;), a fast-growing company engaged in the pharmaceutical wholesale business, through an equity exchange for the issuance of 2,225,000 ordinary shares, which represents 38% of issued and outstanding ordinary shares of the Company after giving effect to the Transactions; and</li>
<li>Divestiture transaction: The sale of Jo-Jo Drugstores' drug retail business to Lei Liu, the current CEO and a director, and Li Qi, a director of the Company, who, together with their affiliates, currently owns approximately 41% of outstanding ordinary shares of the Company, in exchange for a surrender to the Company all shares held by Liu, Qi and their affiliates in the Company totaling 2,548,353 ordinary shares.</li>
</ul>
<div class="lb-trans"><ul>
<li>收购交易：通过发行 2,225,000 股普通股进行股权交换，收购快速成长的药品批发公司 Allright（杭州）互联网科技有限公司（&#34;Allright&#34;），这代表了交易完成后公司已发行和流通普通股的 38%；以及</li>
<li>剥离交易：将九洲大药房的药品零售业务出售给现任首席执行官兼董事刘雷和董事李琦，他们及其关联方目前共同持有公司约 41% 的流通普通股，作为交换，刘、琦及其关联方将向公司交回其持有的共计 2,548,353 股普通股。</li>
</ul>
</div><p>The Transactions are expected to close during the first quarter of 2025, subject to customary closing conditions, including approval by the shareholders of Jo-Jo Drugstores.Following the closing of the Transactions, Liu and Qi are expected to resign from the Board and any other position (including the CEO) of the Company, and the ultimate shareholder of Allright, Lingtao Kong, will join the Board. The parties agree that Frank Zhao, the Company's current CFO, will assume the role of interim CEO to ensure the continued operation of the business and integration of Allright's business.</p>
<div class="lb-trans"><p>预计交易将在 2025 年第一季度完成，需满足包括九洲大药房股东批准在内的惯常成交条件。交易完成后，刘和琦预计将辞去公司董事会及其他任何职务（包括首席执行官），而 Allright 的最终股东孔灵涛将加入董事会。各方同意，公司的现任首席财务官赵峰将担任临时首席执行官，以确保业务的持续运营和 Allright 业务的整合。</p>
</div><p>Mr. Lei Liu, Chairman and CEO of Jo-Jo Drugstores, commented, &#34;This restructuring marks a pivotal moment for CJJD as we transition from a high-cost retail segment to a wholesale-focused model. While I will be shifting my focus to the retail business, an area where I have deep expertise, I believe this transformation will enhance operational efficiency and create long-term value for CJJD's shareholders. I look forward to seeing the wholesale business thrive under the new leadership.&#34;</p>
<div class="lb-trans"><p>九洲大药房董事长兼首席执行官刘雷先生评论道：&#34;此次重组标志着 CJJD 的一个关键时刻，我们将从高成本的零售领域转型为以批发为重点的模式。虽然我将把重心转向我深耕的零售业务，但我相信这一转型将提升运营效率，并为 CJJD 的股东创造长期价值。我期待在新领导下看到批发业务蓬勃发展。&#34;</p>
</div><p>Mr. Lingtao Kong, the ultimate shareholder of Allright and incoming board member, stated, &#34;I am excited to join forces with CJJD as we build a stronger wholesale platform. Allright's growth trajectory aligns well with CJJD's strategic vision, and I am confident that our combined expertise will create new opportunities for expansion and success in the pharmaceutical wholesale market.&#34;</p>
<div class="lb-trans"><p>Allright 的最终股东及即将加入董事会的孔灵涛先生表示：&#34;我很高兴能与 CJJD 携手共建更强大的批发平台。Allright 的增长轨迹与 CJJD 的战略愿景高度契合，我相信我们的专业结合将为药品批发市场创造新的扩展和成功机会。&#34;</p>
</div><p>Mr. Frank Zhao, the current CFO and incoming interim CEO, added, &#34;I am honored to take on this role as interim CEO during this transformative period. I want to thank Mr. Liu for his leadership and dedication in building CJJD into the strong company it is today. As we transition to a wholesale-driven model, I look forward to working closely with Mr. Kong and our team to execute our strategic vision and ensure a seamless integration of Allright's business. Our focus will remain on strengthening our wholesale operations, improving efficiency, and positioning CJJD for long-term success.&#34;</p>
<div class="lb-trans"><p>现任首席财务官及即将担任临时首席执行官的赵峰先生补充道：&#34;在这个转型时期，我很荣幸能担任临时首席执行官。我想感谢刘先生在将 CJJD 建设成今天这样强大公司的领导和奉献。随着我们向以批发为驱动的模式转型，我期待与孔先生及我们的团队紧密合作，执行我们的战略愿景，确保 Allright 业务的无缝整合。我们的重点将继续放在加强批发业务、提高效率，并为 CJJD 的长期成功奠定基础。&#34;</p>
</div><p><strong>AboutChina Jo-JoDrugstores, Inc.</strong></p>
<div class="lb-trans"><p><strong>关于中国九洲大药房公司</strong></p>
</div><p>China Jo-JoDrugstores, Inc. (&#34;Jo-Jo Drugstores&#34; or the &#34;Company&#34;), is a leading online and offline retailer and wholesale distributor of pharmaceutical and other healthcare products and a provider of healthcare services inChina. Jo-Jo Drugstores currently operates an online pharmacy and retail drugstores with licensed doctors on site for consultation, examination and treatment of common ailments at scheduled hours. It is also a wholesale distributor of products similar to those carried in its pharmacies. For more information about the Company, please visithttp://jiuzhou360.com. The Company routinely posts important information on its website.</p>
<div class="lb-trans"><p>中国九洲大药房公司（&#34;九洲大药房&#34;或&#34;公司&#34;）是一家领先的线上和线下零售商及药品和其他健康产品的批发分销商，同时也是中国的医疗服务提供者。九洲大药房目前运营着一家在线药房和零售药店，现场有持证医生提供咨询、检查和常见疾病的治疗。它也是类似于其药房所销售产品的批发分销商。有关公司的更多信息，请访问 http://jiuzhou360.com。公司定期在其网站上发布重要信息。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>This press release contains information about the Company's view of its future expectations, plans and prospects that constitute forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact contained in press release, including statements regarding the benefits of the proposed Transactions and the anticipated timing of the completion of the proposed Transactions, are forward-looking statements. Some of these forward-looking statements can be identified by the use of forward-looking words, including &#34;may,&#34; &#34;should,&#34; &#34;expect,&#34; &#34;intend,&#34; &#34;will,&#34; &#34;estimate,&#34; &#34;anticipate,&#34; &#34;believe,&#34; &#34;predict,&#34; &#34;plan,&#34; &#34;targets,&#34; &#34;projects,&#34; &#34;could,&#34; &#34;would,&#34; &#34;will,&#34; &#34;continue,&#34; &#34;forecast&#34; or the negatives of these terms or variations of them or similar expressions. All forward-looking statements are based upon estimates, forecasts and assumptions that, while considered reasonable by the Company and its management, are inherently uncertain. Actual results may differ materially from historical results or those indicated by these forward-looking statements as a result of a variety of factors including, but not limited to, risks and uncertainties associated with the Company's ability to complete the Transactions in a timely manner or at all, its ability to implement its business plans and strategies, its ability to raise additional funding, its ability to maintain and grow its business, fluctuations in wholesale pricing and demand for pharmaceutical products, variability of operating results, its ability to maintain and enhance its brand, its development and introduction of new products and services, the successful integration of acquired companies, technologies and assets into its portfolio of products and services, marketing and other business development initiatives, its relationships with suppliers and healthcare providers, competition in the industry, general government regulation, economic conditions, dependence on key personnel, the ability to attract, hire and retain personnel who possess the technical skills and experience necessary to meet the requirements of its clients, and its ability to protect its intellectual property. The Company's encourages you to review other risk factors that may affect its future results in the Company's annual reports and in its other filings with the Securities and Exchange Commission (the &#34;SEC&#34;).</p>
<div class="lb-trans"><p>本新闻稿包含关于公司未来预期、计划和前景的信息，这些信息构成了 1995 年美国私人证券诉讼改革法案、1933 年证券法第 27A 条及 1934 年证券交易法第 21E 条所定义的前瞻性声明。新闻稿中除历史事实声明外的所有声明，包括关于拟议交易的好处和预计完成时间的声明，均为前瞻性声明。这些前瞻性声明中的一些可以通过使用前瞻性词汇来识别，包括 “可能”、“应该”、“期望”、“打算”、“将”、“估计”、“预期”、“相信”、“预测”、“计划”、“目标”、“项目”、“可以”、“会”、“将”、“继续”、“预测” 或这些术语的否定形式或变体或类似表达。所有前瞻性声明均基于估计、预测和假设，尽管公司及其管理层认为这些是合理的，但本质上是不确定的。实际结果可能因多种因素而与历史结果或这些前瞻性声明所指示的结果有重大差异，包括但不限于与公司及时完成交易或根本无法完成交易的能力、实施其商业计划和战略的能力、筹集额外资金的能力、维持和发展其业务的能力、批发定价和药品需求的波动、经营结果的变化、维持和提升品牌的能力、新产品和服务的开发和推出、成功整合收购的公司、技术和资产到其产品和服务组合中的能力、市场营销和其他业务发展举措、与供应商和医疗服务提供者的关系、行业竞争、一般政府监管、经济状况、对关键人员的依赖、吸引、招聘和留住具备满足客户要求的技术技能和经验的人员的能力，以及保护其知识产权的能力。公司鼓励您查看可能影响其未来结果的其他风险因素，这些因素在公司的年度报告和向证券交易委员会（“SEC”）的其他文件中有所披露。</p>
</div><p>You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. The Company does not any assurance that the post-combination company will achieve its expected results. The Company does not undertakes any duty to update these forward-looking statements, except as otherwise required by law.</p>
<div class="lb-trans"><p>您不应对前瞻性声明过度依赖，这些声明仅在作出时有效。公司不保证合并后的公司将实现其预期结果。除法律另有要求外，公司不承担更新这些前瞻性声明的义务。</p>
</div><p><strong>Important Information About the Proposed Transactions and Where to Find It</strong></p>
<div class="lb-trans"><p><strong>关于拟议交易的重要信息及获取途径</strong></p>
</div><p>This press release relates to certain proposed Transactions involving Jo-Jo Drugstores. The Company will file a proxy statement with the SEC in connection with the Transactions. A proxy statement will be sent to all Company shareholders as of the applicable record date established for voting on the Transactions. The Company will also file other documents regarding the Transactions with the SEC.</p>
<div class="lb-trans"><p>本新闻稿涉及与九洲大药房相关的某些拟议交易。公司将向 SEC 提交与交易相关的代理声明。代理声明将发送给截至投票交易的适用记录日期的所有公司股东。公司还将向 SEC 提交与交易相关的其他文件。</p>
</div><p>Before making any voting decision, shareholders are urged to read the proxy statement, any amendments thereto, and all other relevant documents filed or that will be filed with the SEC in connection with the Transactions as they become available because they will contain important information about the Company and the Transactions.</p>
<div class="lb-trans"><p>在做出任何投票决定之前，建议股东阅读代理声明、任何修订及所有其他与交易相关的相关文件，这些文件将在与交易相关时提交给 SEC，因为它们将包含关于公司和交易的重要信息。</p>
</div><p>Investors and shareholders will be able to obtain free copies of the proxy statement and all other relevant documents filed or that will be filed with the SEC by the Company through the website maintained by the SEC at www.sec.gov. The documents filed by the Company with the SEC also may be obtained free of charge at the Company's website at http://jiuzhou360.com/investors/sec_filings.</p>
<div class="lb-trans"><p>投资者和股东可以通过 SEC 维护的网站 www.sec.gov 免费获取代理声明及公司向 SEC 提交的所有其他相关文件。公司向 SEC 提交的文件也可以在公司网站 http://jiuzhou360.com/investors/sec_filings 上免费获取。</p>
</div><p>NEITHER THE SEC NOR ANY STATE SECURITIES REGULATORY AGENCY HAS APPROVED OR DISAPPROVED THE TRANSACTIONS DESCRIBED IN THIS COMMUNICATION, PASSED UPON THE MERITS OR FAIRNESS OF THE TRANSACTION OR RELATED TRANSACTIONS OR PASSED UPON THE ADEQUACY OR ACCURACY OF THE DISCLOSURE IN THIS COMMUNICATION. ANY REPRESENTATION TO THE CONTRARY CONSTITUTES A CRIMINAL OFFENSE.</p>
<div class="lb-trans"><p>SEC 或任何州证券监管机构均未批准或不批准本通讯中描述的交易，未对交易或相关交易的优点或公平性进行评估，也未对本通讯中的披露的充分性或准确性进行评估。任何相反的陈述均构成刑事犯罪。</p>
</div><p><strong>No Offer or Solicitation</strong></p>
<div class="lb-trans"><p><strong>无报价或招揽</strong></p>
</div><p>This press release is neither a solicitation of a proxy, an offer to purchase nor a solicitation of an offer to sell any securities and it is not a substitute for any proxy statement or other filings that may be made with the SEC should the proposed Transactions proceed.</p>
<div class="lb-trans"><p>本新闻稿既不是代理的招揽，也不是购买要约或出售任何证券的招揽，也不是任何可能在拟议交易进行时向 SEC 提交的代理声明或其他文件的替代品。</p>
</div><p><strong>For more information, please contact:</strong></p>
<div class="lb-trans"><p><strong>如需更多信息，请联系：</strong></p>
</div><p><strong>Company Contact:</strong></p>
<div class="lb-trans"><p><strong>公司联系人：</strong></p>
</div><p>Frank Zhao</p>
<div class="lb-trans"><p>Frank Zhao</p>
</div><p>Chief Financial Officer</p>
<div class="lb-trans"><p>首席财务官</p>
</div><p>+86-571-88077108</p>
<div class="lb-trans"><p>+86-571-88077108</p>
</div><p>frank.zhao@jojodrugstores.com</p>
<div class="lb-trans"><p>frank.zhao@jojodrugstores.com</p>
</div><p><strong>Investor Relations Contact:</strong></p>
<div class="lb-trans"><p><strong>投资者关系联系人：</strong></p>
</div><p>Tina Xiao</p>
<div class="lb-trans"><p>Tina Xiao</p>
</div><p>Ascent Investor Relations LLC</p>
<div class="lb-trans"><p>Ascent Investor Relations LLC</p>
</div><p>+1-646-932-7242</p>
<div class="lb-trans"><p>+1-646-932-7242</p>
</div><p>investors@ascent-ir.com</p>
<div class="lb-trans"><p>investors@ascent-ir.com</p>
</div><p>SOURCE China Jo-Jo Drugstores, Inc.</p>
<div class="lb-trans"><p>来源：中国九洲大药房股份有限公司</p>
</div>

China Jo-Jo Drugstores Announces Strategic Business Restructuring to Strengthen Wholesale Business for Greater Profitability and Growth | CJJD Stock News

StockTitan

九洲大药房宣布战略业务重组，以加强批发业务，实现更高的盈利和增长 | CJJD 股票新闻